| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 03/01/2007 | US20070048392 Plant extract mixtures and their uses |
| 03/01/2007 | US20070048298 administering nucleoproteins such as retinoblastoma associated protein 48 suppressor or inhibitors, used for prophylaxis of Sjogren's syndrome, as diagnostic agents or screening antiapoptosic agents |
| 03/01/2007 | US20070048291 Method and material for enhanced tissue-biomaterial integration |
| 03/01/2007 | US20070048286 Method of treating dopaminergic and GABA-nergic disorders |
| 03/01/2007 | CA2620202A1 Therapy procedure for drug delivery for trigeminal pain |
| 03/01/2007 | CA2617975A1 Combination of a hypnotic agent and r(+)-alpha-(2,3-dimethoxy-phenyl)-1-[2-(4-fluorophenl)ethyl]-4-piperidinemethanol and therapeutic application thereof |
| 03/01/2007 | CA2617519A1 Agent for treating atrial fibrillation |
| 02/28/2007 | EP1757937A2 Antagonists of HMG1 for treating inflammatory conditions |
| 02/28/2007 | EP1757692A1 GENE ENCODING GUANINE NUCLEOTIDE EXCHANGE FACTOR BINDING TO RhoA |
| 02/28/2007 | EP1757690A1 Gene encoding guanine nucleotide exchange factor and its gene product |
| 02/28/2007 | EP1757618A2 Angiogenesis-associated proteins, and nucleic acids encoding the same |
| 02/28/2007 | EP1757600A2 Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance |
| 02/28/2007 | EP1757321A2 Methods and apparatus for relieving headaches, rhinitis and other common ailments |
| 02/28/2007 | EP1757307A1 Method of regenerating follicles by inhibiting gene capable of inhibting follicle formation or activating gene capable of inducing follicle formation |
| 02/28/2007 | EP1757306A1 Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes |
| 02/28/2007 | EP1757295A1 Peripheral-Type benzodiazepine receptor: a tool for detection, diagnosis, prognosis, and treatment of cancer |
| 02/28/2007 | EP1757289A1 Composition for acceleration of alcohol metabolism or recuperation from fatigue through gluconeogenesis |
| 02/28/2007 | EP1757283A1 Antitumor effect fortifier, antitumor agent and method of therapy for cancer |
| 02/28/2007 | EP1757281A2 Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist |
| 02/28/2007 | EP1757269A2 Pulmonary formulation comprising silicon particles |
| 02/28/2007 | EP1756267A2 Stem cell populations and methods of use |
| 02/28/2007 | EP1756062A1 Compounds and compositions as ppar modulators |
| 02/28/2007 | EP1756058A1 Histamine-3 receptor antagonists |
| 02/28/2007 | EP1756039A2 Compounds and compositions for delivering active agents |
| 02/28/2007 | EP1755682A1 Solid pharmaceutical formulation |
| 02/28/2007 | EP1755681A2 Combination of organic compounds |
| 02/28/2007 | EP1755680A1 Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor |
| 02/28/2007 | EP1755678A2 Active substance combination of a carbinol compound and an opioid |
| 02/28/2007 | EP1755677A2 High pressure spray-dry of bioactive materials |
| 02/28/2007 | EP1755674A2 Prolongation of survival of an allograft by inhibiting complement activity |
| 02/28/2007 | EP1755654A2 Methods and systems for treatment of neurological diseases of the central nervous system |
| 02/28/2007 | EP1755649A1 Selective killing of cancer cells by induction of acetyltransferase via tnf-alpha and il-6 |
| 02/28/2007 | EP1755641A2 Agonists and antagonists of p28, ebi3 and wsx/tccr for treating immune disorders |
| 02/28/2007 | EP1755638A1 Multiple agent therapy for sexual dysfunction |
| 02/28/2007 | EP1755632A1 Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a gst-activated anticancer compound |
| 02/28/2007 | EP1755625A1 Compositions and methods using same for treating neurodegenerative disorders |
| 02/28/2007 | EP1755624A2 Polycationic antimicrobial therapeutic |
| 02/28/2007 | EP1755611A1 Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions |
| 02/28/2007 | EP1755594A1 Combination therapy comprising an adenosine a1 receptor antagonist and an aldosterone inhibitor |
| 02/28/2007 | EP1755591A2 Ophthalmic formulations including selective alpha 1 antagonists |
| 02/28/2007 | EP1755589A1 Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension |
| 02/28/2007 | EP1755587A1 Pharmaceutical compositions comprising higher primary aliphatic alcohols and hmg coa reductase inhibitor and process of preparation thereof |
| 02/28/2007 | EP1755575A2 Antifungal drug delivery |
| 02/28/2007 | EP1755574A2 Pten inhibitors |
| 02/28/2007 | EP1755561A2 Multi-layer tablet comprising non-steroidal anti-inflammatory drugs decongestants and non-sedating antihistamines |
| 02/28/2007 | EP1656128A4 Treatment for acne vulgaris and method of use |
| 02/28/2007 | EP1572179B1 Pharmaceutical composition comprising a ltb4 antagonist and a cox-2 inhibitor or a combined cox1/2 inhibitor |
| 02/28/2007 | EP1441734B1 Dihydroxypyrimidine carboxamide inhibitors of hiv integrase |
| 02/28/2007 | EP1429807B1 Combination of a nsaid and a pde-4 inhibitor |
| 02/28/2007 | EP1381397B1 Stabilisation of radiopharmaceutical compositions using a hydrophilic thioether or a hydrophilic 6-hydroxy chroman |
| 02/28/2007 | EP1379229B1 A jasmonate pharmaceutical composition for treatment of cancer |
| 02/28/2007 | EP1346041B1 Therapeutic agents and methods of use thereof for treating an amyloidogenic disease |
| 02/28/2007 | EP1301201B1 Treatment of glycogen storage disease type ii |
| 02/28/2007 | EP1272186B1 Therapeutic combinations of antihypertensive and antiangiogenic agents |
| 02/28/2007 | EP1178811B1 Electrolyte gels for maintaining hydration and rehydration |
| 02/28/2007 | EP1150695B1 Herbal supplement for increased muscle strength and endurance for athletes |
| 02/28/2007 | EP1079802B1 Formulations for the prevention or the treatment of diseases affecting mucosae or skin, or for pregnancy prevention |
| 02/28/2007 | EP1033979B9 Combination of cyp2a enzyme inhibitors and nicotine and their therapeutic use |
| 02/28/2007 | CN1922171A Pyrimidine derivative |
| 02/28/2007 | CN1921886A Methods of modulating cytokine activity, related reagents |
| 02/28/2007 | CN1921885A Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient |
| 02/28/2007 | CN1921865A Use of meloxicam for the treatment of respiratory diseases in pigs |
| 02/28/2007 | CN1921862A Immunostimulant composition comprising at least one TOLL-like receptor 7 or TOLL-like receptor 8 agonist and a TOLL-like receptor 4 agonist |
| 02/28/2007 | CN1921852A Use of metronidazole for preparing a pharmaceutical composition for treating pathologies related to the b-type receptor of interleukin 8 and/or to a pacap type 1 receptor |
| 02/28/2007 | CN1921851A Use of metronidazole for preparing a pharmaceutical composition for treating a cutaneous inflammation |
| 02/28/2007 | CN1921850A Use of metronidazole for preparing a pharmaceutical composition for treating a cutaneous vascularisation disorder |
| 02/28/2007 | CN1921849A Combination treatment of obesity involving 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity and lipase inhibitors |
| 02/28/2007 | CN1921844A Use of cholinesterase inhibitors for treating vascular depression |
| 02/28/2007 | CN1921820A Composition for treating a dermatological inflammatory response and method of preparation thereof |
| 02/28/2007 | CN1919258A Application of schisandra chinensis in the preparation of medicine for preventing and reducing toxic and side effect of antitumor agent |
| 02/28/2007 | CN1919199A Methods for treating psychosis associated with glucocorticoid related dysfunction |
| 02/28/2007 | CN1919182A Mucosal delivery tablet |
| 02/28/2007 | CN1919181A Amphipathic fluorescence target nano micelle and its preparation method |
| 02/28/2007 | CN1919171A Medicinal composition of nimustine and its progression agent |
| 02/28/2007 | CN1302102C Method for preparing megakaryocytic preparation by amplifying macronucleus ancestral cell and mature megacaryocyte and use |
| 02/28/2007 | CN1302007C Anti-inflammatory 17. beta-carbothioate ester derivatives of androstane with a cyclic ester group in position 17. alpha |
| 02/28/2007 | CN1301994C Diaryl peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 02/28/2007 | CN1301993C Dimeric compounds and their use as anti-viral agents |
| 02/28/2007 | CN1301972C Piperidine compounds as muscarinic antagonists |
| 02/28/2007 | CN1301747C Protein medicine microcapsule and inhalational aerosol thereof |
| 02/27/2007 | US7183321 Antidiabetic formulation and method |
| 02/27/2007 | US7183307 Pyrazole-derived kinase inhibitors and uses thereof |
| 02/27/2007 | US7183302 Iminothiazolidinones as inhibitors of HCV replication |
| 02/27/2007 | US7183273 Administering compounds such as N-(2-pyridinylmethyl)-N'-(6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl)-1,4-benzenedimethanamine for therapy of disease mediated by a chemokine receptor |
| 02/27/2007 | US7183266 Dual induced viscosity fiber system and uses thereof |
| 02/27/2007 | US7183265 Powdery product comprising crystalline β-maltose monohydrate, its preparation, and uses |
| 02/27/2007 | US7183254 Diagnosis, hormone replacement therapy for HIV positive females, gene therapy; metabolic disorders; antidiabetic, anticholesterol, hypoglycemic agents |
| 02/27/2007 | US7183251 hCG therapy for the treatment of breast cancer |
| 02/27/2007 | US7183112 Administering locally to the area of inflammation to an animal an anti-inflammatory effective amount of an anti-malaria compound which is aminoquinoline or derivative |
| 02/27/2007 | US7183095 Cell culture system for synthesis of infectious hepatitis C virus |
| 02/27/2007 | US7183078 Nucleotide sequences coding mammalian histamine H4 receptor protein for use in diagnosis, prevention and treatment of asthma, allergy, inflammation, thrombotic, cardiovascular and autoimmune disorders |
| 02/27/2007 | US7183075 Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same |
| 02/27/2007 | US7183070 Using reduction in beta site amyloid precursor protein cleaving enzyme activity, manifested as decreased beta amyloid peptides production, as diagnostic indicator of enzyme inhibition; for use in treatment of amyloid deposition disorders |
| 02/27/2007 | US7183063 Can be used in screening for agents which act as antagonists to MCP-1, MIP-1 alpha and/or RANTES |
| 02/27/2007 | US7182962 Swine plasma albumin; gene expression of immunostimulant; prevent infections; anticancer agents |
| 02/27/2007 | US7182953 Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
| 02/27/2007 | US7182948 Topical veterinary compositions and methods for the treatment and prevention of infection |
| 02/27/2007 | US7182942 Vaccine immunotherapy for immune suppressed patients |
| 02/27/2007 | CA2432798C Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
| 02/27/2007 | CA2352571C In vivo biosensor apparatus and method of use |